Primary Hyperoxaluria Pipeline Report, 2023 Updates: In-depth Analysis into the Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Emerging Drugs, and Growth Prospects | Competition Deep Dive, Alnylum Pharma, OxThera, Dicerna Pharmaceuticals, Inc., All

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Primary Hyperoxaluria pipeline constitutes 8+ key companies continuously working towards developing 8+ Primary Hyperoxaluria treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Primary Hyperoxaluria Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Primary Hyperoxaluria Market.

The Primary Hyperoxaluria Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Primary Hyperoxaluria Pipeline Report: https://www.delveinsight.com/sample-request/primary-hyperoxaluria-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Primary Hyperoxaluria treatment therapies with a considerable amount of success over the years.
• Primary Hyperoxaluria companies working in the treatment market are Chinook Therapeutics, Cantero Therapeutics, BioMarin Pharmaceutical, Inc, OxThera, Dicerna Pharmaceuticals, Inc, and others, are developing therapies for the Primary Hyperoxaluria treatment
• Emerging Primary Hyperoxaluria therapies in the different phases of clinical trials are- CHK-336, BBP-711, BMN 255, Oxabact, Nedosiran, and others are expected to have a significant impact on the Primary Hyperoxaluria market in the coming years.
• In September 2022, Nedosiran was submitted by Novo Nordisk to the US FDA for regulatory approval.
• In February 2022, In order to assess the safety, pharmacokinetics, and efficacy of Nedosiran in paediatric patients from birth to 11 years of age with primary hyperoxaluria and reasonably intact renal function, Dicerna Pharmaceuticals, Inc. started a Phase II open-label multicenterstudy
• In December 2021, The completion of the acquisition of Dicerna Pharmaceuticals, Inc. was announced by Novo Nordisk.Novo Nordisk has bought all outstanding shares of common stock of Dicerna for a price of USD 38.25 per share in cash, without interest, and less any relevant tax withholding, following the expiration of Novo Nordisk's cash tender offer for Dicerna
• In 2020, The FDA of the United States approved Oxlumo (lumasiran) as the first line therapy for primary hyperoxaluria type 1 (PH1), a rare inherited condition. The Kidney Health Initiative and the Oxalosis & Hyperoxaluria Foundation worked together to coordinate the efforts of professionals and community people, which resulted in this ground-breaking approval

Primary Hyperoxaluria Overview
A series of rare inherited metabolic illnesses known as Primary Hyperoxaluria (PH) are characterised by the buildup of the chemical oxalate in the kidneys and other organ systems of the body. A particular enzyme that typically inhibits the accumulation of oxalate is absent from affected people.

Get a Free Sample PDF Report to know more about Primary Hyperoxaluria Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/primary-hyperoxaluria-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Primary Hyperoxaluria Drugs Under Different Phases of Clinical Development Include:
• CHK-336: Chinook Therapeutics
• BBP-711: Cantero Therapeutics
• BMN 255: BioMarin Pharmaceutical, Inc
• Oxabact: OxThera
• Nedosiran: Dicerna Pharmaceuticals, Inc
• DCR-PHXC: Dicerna Pharmaceuticals

Primary Hyperoxaluria Route of Administration
Primary Hyperoxaluria pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
• Molecule Type

Primary Hyperoxaluria Molecule Type
Primary Hyperoxaluria Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Primary Hyperoxaluria Pipeline Therapeutics Assessment
• Primary Hyperoxaluria Assessment by Product Type
• Primary Hyperoxaluria By Stage and Product Type
• Primary Hyperoxaluria Assessment by Route of Administration
• Primary Hyperoxaluria By Stage and Route of Administration
• Primary Hyperoxaluria Assessment by Molecule Type
• Primary Hyperoxaluria by Stage and Molecule Type

DelveInsight's Primary Hyperoxaluria Report covers around 8+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Primary Hyperoxaluria product details are provided in the report. Download the Primary Hyperoxaluria pipeline report to learn more about the emerging Primary Hyperoxaluria therapies at:

Some of the key companies in the Primary Hyperoxaluria Therapeutics Market include:
Key companies developing therapies for Primary Hyperoxaluria are - Competition Deep Dive, Alnylum Pharma, OxThera, Dicerna Pharmaceuticals, Inc., Allena Pharmaceuticals, Biocodex, Tecoland Corporation, Zhejiang Tianxin Pharmaceutical Co., Takeda Pharmaceuticals, Wuxi Further Pharmaceutical Co Ltd, Genentech, and others.

Primary Hyperoxaluria Pipeline Analysis:
The Primary Hyperoxaluria pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Primary Hyperoxaluria with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Primary Hyperoxaluria Treatment.
• Primary Hyperoxaluria key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Primary Hyperoxaluria Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Primary Hyperoxaluria market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Primary Hyperoxaluria drugs and therapies-
https://www.delveinsight.com/sample-request/primary-hyperoxaluria-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Primary Hyperoxaluria Pipeline Market Drivers
• Rising Prevalence of Primary hyperoxaluria, increasing demand of disease specific novel treatment are some of the important factors that are fueling the Primary Hyperoxaluria Market.

Primary Hyperoxaluria Pipeline Market Barriers
• However, high cost of treatment and diagnosis for Hyperoxaluria, limited research and development for treatment and other factors are creating obstacles in the Primary Hyperoxaluria Market growth.

Scope of Primary Hyperoxaluria Pipeline Drug Insight
• Coverage: Global
• Key Primary Hyperoxaluria Companies: Chinook Therapeutics, Cantero Therapeutics, BioMarin Pharmaceutical, Inc, OxThera, Dicerna Pharmaceuticals, Inc, and others
• Key Primary Hyperoxaluria Therapies: CHK-336, BBP-711, BMN 255, Oxabact, Nedosiran, and others
• Primary Hyperoxaluria Therapeutic Assessment: Primary Hyperoxaluria current marketed and Primary Hyperoxaluria emerging therapies
• Primary Hyperoxaluria Market Dynamics: Primary Hyperoxaluria market drivers and Primary Hyperoxaluria market barriers

Request for Sample PDF Report for Primary Hyperoxaluria Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/primary-hyperoxaluria-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Primary Hyperoxaluria Report Introduction
2. Primary Hyperoxaluria Executive Summary
3. Primary Hyperoxaluria Overview
4. Primary Hyperoxaluria- Analytical Perspective In-depth Commercial Assessment
5. Primary Hyperoxaluria Pipeline Therapeutics
6. Primary Hyperoxaluria Late Stage Products (Phase II/III)
7. Primary Hyperoxaluria Mid Stage Products (Phase II)
8. Primary Hyperoxaluria Early Stage Products (Phase I)
9. Primary Hyperoxaluria Preclinical Stage Products
10. Primary Hyperoxaluria Therapeutics Assessment
11. Primary Hyperoxaluria Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Primary Hyperoxaluria Key Companies
14. Primary Hyperoxaluria Key Products
15. Primary Hyperoxaluria Unmet Needs
16 . Primary Hyperoxaluria Market Drivers and Barriers
17. Primary Hyperoxaluria Future Perspectives and Conclusion
18. Primary Hyperoxaluria Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Primary Hyperoxaluria Market https://www.delveinsight.com/report-store/primary-hyperoxaluria-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Primary Hyperoxaluria-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Primary Hyperoxaluria Epidemiology https://www.delveinsight.com/report-store/primary-hyperoxaluria-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Primary Hyperoxaluria Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:

Monkeypox Market https://www.delveinsight.com/report-store/monkeypox-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Monkeypox Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Monkeypox, historical and forecasted epidemiology as well as the Monkeypox market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Pars Planitis Market
https://www.delveinsight.com/report-store/pars-plantis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Pars Plantis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Pars Plantis, historical and forecasted epidemiology as well as the Pars Plantis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Patient Monitoring Devices Market
https://www.delveinsight.com/report-store/patient-monitoring-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Patient Monitoring Devices Market By Type Of Devices (Neuromonitoring Devices, Cardiac Monitoring Devices, Respiratory Monitoring Devices, Hemodynamic Monitoring Devices, Blood Glucose Monitoring Systems, And Others), By Application (Cardiology, Neurology, Respiratory, And Others), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, And Others), by geography, is anticipated to grow at a significant CAGR till 2028 owing to the growing prevalence of various chronic disorders and integration of advanced technology in the products

Typhoid Market https://www.delveinsight.com/report-store/typhoid-fever-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Typhoid Fever Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Typhoid Fever, historical and forecasted epidemiology as well as the Typhoid Fever market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Zika Virus Market https://www.delveinsight.com/report-store/zika-virus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Zika Virus Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Zika Virus, historical and forecasted epidemiology as well as the Zika Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Opioid Use Disorder Market https://www.delveinsight.com/report-store/opioid-use-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Opioid Use Disorder (OUD) - Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Opioid Use Disorder (OUD), historical and forecasted epidemiology as well as the Opioid Use Disorder (OUD) market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Recent Blog's By DelveInsight:
• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.